ABSTRACT
The authors have treated: a) 48 cases of E. histolytica histolytica intestinal amoebiasis by a single dose of 35 mg/kg of secnidazole with 98 p. 100 of parasitological success; b) 122 cases of E. histolytica minuta with several procedures: a unique dose of 25 mg/kg gives no success in 16.6 p. 100 of the cases, but the same single dose during three days gets only 2 p. 100 of failure; c) 22 cases of hepatic amoebiasis by a daily dose of 25 to 33 mg/kg during 5 days with success in every cases. Tolerance has been excellent. These short cures, facilitated by the long half-life of secnidazole are particularly easy to apply in developing countries.
Subject(s)
Amebiasis/drug therapy , Entamoebiasis/drug therapy , Metronidazole/analogs & derivatives , Adult , Child , Drug Administration Schedule , Dysentery, Amebic/drug therapy , Female , Humans , Liver Abscess, Amebic/drug therapy , Male , Metronidazole/administration & dosage , Metronidazole/adverse effectsSubject(s)
Intestinal Diseases, Parasitic/epidemiology , Schistosomiasis/epidemiology , Adolescent , Child , Cote d'Ivoire , Female , Humans , Male , Sampling Studies , Schistosoma mansoniABSTRACT
Reporting 75 original cases the authors review the clinical radiological and biological syndroma of hepatitic amoebiasis. They emphasize the recent advances in medical treatments which frequently give opportunity of avoiding surgery. But surgical intervention cannot be systematically discarded and has been necessary in 11 p. 100 of the reported cases. Drainage strengthens drugs efficiency. Antibiotherapy is generally useless.
